Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending legal disputes and ensuring continued access to Yutrepia for PAH patients. However, the company must pay $380.7 million in settlement obligations across 2026-2027, and the removal of the PH-ILD indication from Yutrepia's label narrows its approved use. The company reported preliminary Q3 2026 Yutrepia sales of $222.7 million and plans to advance pipeline candidate L606.

In a comparison of two medical-drugs stocks, Shionogi & Co., Ltd. (SGIOY) emerges as the superior value option compared to United Therapeutics (UTHR). SGIOY holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a lower forward P/E ratio of 10.68 versus UTHR's 20.59, and a more favorable P/B ratio of 1.34 compared to UTHR's 3.64. UTHR carries a Zacks Rank #3 (Hold) with a Value grade of C.

The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies potential earnings surprises by comparing the Most Accurate Estimate to the Zacks Consensus Estimate. Historical data shows that combining a positive ESP with a Zacks Rank #3 or better has resulted in positive earnings surprises 70% of the time, with average annual returns of 28.3%. The article highlights Halozyme Therapeutics and United Therapeutics as examples of stocks with positive ESP figures ahead of their earnings releases.

The article explains how the Zacks Earnings ESP (Expected Surprise Prediction) filter helps investors identify stocks likely to beat earnings expectations by comparing the most recent analyst estimates against consensus estimates. Two examples highlighted are United Therapeutics (UTHR) with a +4.99% ESP and Eli Lilly (LLY) with a +1.21% ESP, both positioned to potentially surprise positively in their upcoming earnings reports.

A Delaware federal court ruled on September 30, 2026, that Liquidia Corporation's lead product Yutrepia inhalation powder infringed two claims of United Therapeutics' patent for treating pulmonary hypertension. The ruling triggered a sharp 57.2% stock price decline from $70.69 to $30.26 per share. Liquidia's CEO stated the company plans to pursue appellate options. A law firm is now investigating potential securities law violations on behalf of stockholders.

A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.

United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement.

United Therapeutics shares surged 12.5% following a Delaware court ruling that Liquidia's Yutrepia infringes on UTHR's patent for inhaled treprostinil, potentially restricting competition for UTHR's Tyvaso products. However, the stock faces headwinds as consensus EPS estimates were revised 1.4% lower over the past 30 days, and the company is expected to report declining earnings and flat revenue growth.

Liquidia's lead drug Yutrepia has gained significant market traction with over 5,000 patients started on therapy as of July 2026, but the stock has underperformed due to heavy reliance on a single product, ongoing patent litigation with United Therapeutics, competitive pressures, and rising R&D costs. Analysts recommend avoiding the stock due to an unfavorable risk-reward profile.

Altimmune reported a Q2 2026 loss of 12 cents per share, beating the consensus estimate of 15 cents, with no revenues as the company lacks marketed drugs. R&D expenses rose 8.2% to $18.7 million, primarily due to ongoing MASH clinical studies. The company's cash position strengthened to $519 million, supporting operations into 2029. Shares have gained 14.2% over the past month, outperforming the S&P 500, though the stock carries a Zacks Rank #3 (Hold) rating with an overall VGM Score of F.

United Therapeutics announced FDA acceptance of a supplemental new drug application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF), with a regulatory decision expected in late April 2027. The TETON phase III studies demonstrated statistically significant improvements in lung function, including a 111.8 mL FVC benefit, reduced clinical worsening, and favorable secondary endpoints. If approved, Tyvaso would be the first FDA-approved inhaled anti-fibrotic treatment for IPF.

Liquidia Corporation's lead drug Yutrepia generated $300.3 million in first-half 2026 sales, driving the company's fourth consecutive profitable quarter. However, the pulmonary arterial hypertension (PAH) market faces intense competition from established therapies and pipeline candidates from United Therapeutics and Insmed. Liquidia plans to expand Yutrepia into additional indications including COPD, IPF, PPF, and Raynaud's phenomenon to sustain long-term growth.